Precursor Revenue and Competitors
Estimated Revenue & Valuation
- Precursor's estimated annual revenue is currently $729k per year.
- Precursor's estimated revenue per employee is $121,500
Employee Data
- Precursor has 6 Employees.
Precursor's People
Name | Title | Email/Phone |
---|---|---|
1 | Co-Founder | Reveal Email/Phone |
Precursor Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $90.1M | 435 | -26% | $356.2M | $2B |
#2 | $14M | 64 | N/A | N/A | N/A |
#3 | $1.8M | 25 | -32% | $7.3M | N/A |
#4 | $3.9M | 34 | N/A | N/A | N/A |
#5 | $4.7M | 43 | -7% | $47.6M | N/A |
#6 | $3.8M | 59 | N/A | N/A | N/A |
#7 | N/A | 3 | N/A | N/A | N/A |
#8 | $1.9M | 32 | 3% | N/A | N/A |
#9 | $35.9M | 225 | N/A | N/A | N/A |
#10 | $9.1M | 70 | N/A | N/A | N/A |
#11 | N/A | 29 | N/A | N/A | N/A |
#12 | $5.1M | 44 | N/A | N/A | N/A |
#13 | $0.4M | 3 | N/A | N/A | N/A |
#14 | $0.7M | 9 | N/A | N/A | N/A |
What Is Precursor?
N/A
Total Funding
6
Number of Employees
$729k
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Precursor News
2022-04-20 - CBD Precursor Results in Anti-seizure Effects in Dravet Mouse ...
Olivetolic acid, a precursor of cannabidiol (CBD), resulted in protective effects against fever-induced seizures in a mouse model of Dravet...
2022-04-20 - China Ternary Cathode Material Precursor Output Likely to ...
According to SMM research, China's ternary cathode material precursor is expected to drop by more than 15% MoM in April.
2022-04-17 - Multiple myeloma defies early detection. This precursor could ...
Multiple myeloma is usually detected late. Some researchers think a precursor could help catch it early. Angus Chen. By Angus Chen April 21, 2022.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.4M | 6 | -25% | N/A |
#2 | $0.1M | 6 | -25% | $31M |
#3 | $0.1M | 6 | 0% | $22.4M |
#4 | $0.1M | 6 | 0% | $6.8M |
#5 | $0.4M | 6 | N/A | N/A |